Mode
Text Size
Log in / Sign up
N/A N=378 Other

Connecting Resources for Urban Sexual Health

HIV · Sexually Transmitted Infections

Enrolled (actual)
378
Serious AEs
0.0%
Results posted
Dec 2024
Primary outcome: Primary: The Proportion of Young Men Who Have Sex With Men (YMSM) Who Test Positive for HIV at Enrollment — 70; 28; 280 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Testing and linkage to care for Y/MSM (Other); Engagement and retention for HIV-positive Y/MSM in care (Behavioral); Engagement and retention for HIV-negative Y/MSM in sexual health services (Other); Stribild PEP Substudy (Drug)
Age
Adult · 18+ yrs
Sex
Male
Sponsor
University of California, San Francisco
Primary completion
Mar 2017

Outcome Measures

OutcomeResultp-value
PRIMARY
The Proportion of Young Men Who Have Sex With Men (YMSM) Who Test Positive for HIV at Enrollment
70; 28; 280
PRIMARY
The Proportion of HIV-positive Enrolled YMSM Who Are Retained, on Therapy, and Who Have Achieved Viral Suppression Within One Year of Entering Care
81; 52; 47
PRIMARY
The Proportion of HIV-uninfected YMSM Participants Who Are Retained, Receive Sexually Transmitted Infection (STI) Testing, and Receive Non-occupational Post-exposure-prophylaxis (nPEP) and/or PrEP
243; 14; 188; 69; 239; 18
PRIMARY
Substudy Primary Outcome: The Tolerability and Acceptability of a 28 Day Course of Stribild® Given as Post-exposure Prophylaxis (PEP) to Prevent Sexual Acquisition of HIV-1
69
SECONDARY
Substudy Secondary Outcome: The Renal Safety of Stribild® PEP
.0380
SECONDARY
Substudy Secondary Outcome: Change From 1 Week to 4 Weeks in eGFR
-1.4286
SECONDARY
Substudy Secondary Outcome: To Assess the Renal Safety of Stribild® PEP
SECONDARY
Substudy Secondary Outcome: To Document Any HIV-1 Seroconversions Occurring While on Stribild® PEP
SECONDARY
Substudy Secondary Outcome: To Assess Adherence to Stribild® PEP
11
SECONDARY
Substudy Secondary Outcome: To Assess Adherence to Stribild® PEP
11
SECONDARY
Substudy Secondary Outcome: To Assess Adherence to Stribild® PEP
11
SECONDARY
Substudy Secondary Outcome: To Assess Adherence to Stribild® PEP
11

Summary

The overall goal of the CRUSH project is to enhance and extend a response to the local HIV/AIDS epidemic in Alameda County with a set of innovative, evidence-based interventions across the continuum of HIV prevention and care, targeting individuals and communities most vulnerable to HIV. The East Bay AIDS Center, in partnership with the University of California San Francisco's Center for AIDS Prevention Studies, the Gladstone Institutes, and several key community-based organizations, are engaging in a participatory partnership to enhance and implement HIV services which target the East Bay's highest risk population- young men who have sex with men (Y/MSM). Specifically, the CRUSH Project is designed to evaluate a combination of program approaches to address the sexual health care needs of young gay men of color and their sexual partners by enhancing the current program activities of the Downtown Youth Clinic (DYC). We hypothesize that we can reduce the impact of HIV among Y/MSM by expanding the current DYC services structure in two ways. We intend to expand HIV testing, and linkage to and retention in care for youth who test HIV positive, providing them with intensive risk-reduction counseling and antiretroviral treatment, and thereby ultimately reducing the risk of further HIV transmission. And we intend for the first time to offer a comprehensive combination package of preventive services to HIV-negative youth, including routine accesses to HIV/STI screening and treatment, and access to HIV pre-exposure prophylaxis (PrEP). The CRUSH Project will also have a substudy that will enroll HIV-negative participants who are eligible to receive PEP. The substudy will evaluate the tolerability and acceptability of a 28 day course of Stribild® given as post-exposure prophylaxis (PEP) to prevent sexual acquisition of HIV-1 in Y/MSM of color.

Eligibility Criteria

Inclusion Criteria

  • Men between the ages of 18-29 who are ever sexually active with men;
  • Transgender females (M2F) between the ages of 18-29 who are sexually active with men; Transgender males (F2M) between the ages of 18-29 who are sexually active with men; and
  • Any HIV-negative person aged 18-29, male or female, who has at least one known HIV positive (i.e. serodiscordant) sexual partner.

Exclusion Criteria

  • None.

For the PEP substudy the inclusion criterion is at least one episode in the 72 hours prior to presentation of unprotected receptive anal intercourse with a partner known or suspected to be HIV positive and the following are the substudy exclusion criteria:

  • Known kidney disease
  • Dipstick proteinuria >1+
  • eGFR < 70 ml/min/1.73m2
  • Known metabolic bone disease
  • Signs or symptoms of acute HIV infection
  • Concomitant use of nephrotoxic drug or medication contraindicated with Stribild®
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02183909). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search